Endocrine Abstracts

SH is defined by a decrease of TSH with normal thyroid hormone (TH) concentrations. The clinical picture is not clear, whether these patients may have symptoms or alterations of QoL. It is well known that in overt hyperthyroidism, symptoms may be absent in old patients. In SH, one study in young patients has reported an increased symptom score and a slight decrease of QoL but these results have not been confirmed in middle-aged subjects. We report the initial data of the Pirat...

Persistence of elevated TSH levels despite large doses of L-thyroxin is not uncommon, although thyroxin substitution is usually easy and convenient. The first cause to be considered is thyroxin malabsorption, whether organic, due to concomitant gastric or intestinal disease, or bariatric surgery, or, more frequently, related to dietary or drug interference. Proton-pump inhibitors, antacids and a long list of drugs may decrease thyroxin absorption. Drugs and thyr...

Hemoglobin A1c (HbA1c) is used for the long-term management of patients with diabetes mellitus (DM). Hemoglobin variants other than HbA1c and e-N-lysine-glycated HbA0 may cause analytical interference in determinations of HbA1c. Hemoglobin J is an abnormal hemoglobin, an alpha globin gene variant and present in various geographic locations. Hemoglobin J (depending on its type) has different characteristics and functions. For example hemoglobin J Capetown (α2 92Gln β2...

Objective: To investigate the results of J – 131 treatments in patients (pts) with autonomous thyroid adenomas in long period of follow up.Material and Methods: We enrolled 68 consecutive pts with Plummer’s disease (50 females, 18 males, mean age 54,7 yrs, range 21 – 79 yrs) for period 2000 – 2020 yrs. 87%(59/68) pts had a unifocal nodule, while 13% (9/68) pts had multifocal toxic autonomous nodules. Pts stopped antithyroid drugs for ...

J J Kopchick, Ohio University, Athens, Ohio, USA. AbstractDr John J Kopchick is an internationally recognized leader in the growth hormone (GH) field. Since 1987, he has held the Milton and Lawrence H Goll Eminent Scholar Professorship in Molecular and Cellular Biology and directs the Growth/Obesity/Diabetes Section of the Edison Biotechnology Institute at Ohio University in Athens, Ohio. He also is Professor in the B...

Oncogenic activation of MAPK in thyroid cells leads to loss of expression of genes required for thyroid hormone biosynthesis, including the sodium iodide transporter (NIS) and thyroid peroxidase (TPO). Tumors with BRAF mutation have lower expression of NIS, explaining in part why BRAF-mutant PTCs are often resistant to RAI therapy. We developed mouse models of thyroid cancer driven by BRAFV600E, and these tumors also lose the ability to concentrate radioiodine, whic...

J Wass, Department of Endocrinology, OCDEM, Churchill Hospital, Oxford, UK AbstractJohn Wass is the Professor of Endocrinology at Oxford University and Head of the Department of Endocrinology at the Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital Oxford, UK. He qualified at Guy’s in 1971 and did his endocrine training at Bart’s. He got his MD from the University of London in 1980....

J Connell, University of Glasgow, Glasgow, United Kingdom Abstract John Connell graduated in medicine from the University of Glasgow (with commendation) in 1977. After initial general medical training he was appointed Registrar in Endocrinology in the Western Infirmary, Glasgow; in 1983 he became Clinical Scientist within the MRC Blood Pressure Unit and Senior Registrar in Endocrinology. In 1986 he was awarded a ...

There is no doubt that the use of a syringe and needle has led to an important cost effective strategy for the investigation of thyroid nodules by fine needle aspiration biopsy (FNAB) with cytological examination of the aspirate. A recent European Thyroid Association survey found that 99% of respondents used FNAB (Bennedbaek et al 1999). However, there are limitations of FNAB including false negatives, false positives, inadequate specimens and reporting, accessibility of nodul...

Peter J Fuller, Prince Henry’s Institute, Clayton, Victoria, Australia. AbstractProfessor Fuller is an NHMRC Senior Principal Research Fellow at Prince Henry's Institute of Medical Research in Melbourne where is the Associate Director and Head of the Steroid Receptor Biology Group. He is also Director of the Endocrinology Unit at the Monash Medical Centre/Southern Health and an Adjunct Professor in Medicine and ...